Navigation Links
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
Date:5/14/2009

" target="_new">http://investors.trubion.com/index.cfm.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the Company's future clinical development programs and the timing thereof, the Company's future regulatory filings and the timing and outcome thereof. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the clinical advancement of TRU-016, the Company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, and such other risks as identified in the Company's quarterly report on Form 10-Q for the period ended March 31, 2009, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500
    jdenike@trubion.com
   
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
2. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
7. Trubion Announces Presentations at Upcoming Investor Conferences
8. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s ... reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
(Date:7/29/2015)... According to a new market research report, ... , published by Mordor Intelligence, the Global market is expected ... 2020, with North America being the ... global market size. The Global market for Stem Cells is ... period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)... BIRMINGHAM, Ala., July 29, 2015 /PRNewswire/ ... the nation,s largest providers of post-acute healthcare services, ... reported its results of operations for the second ... second quarter was characterized by strong volume growth ... our Adjusted EBITDA," said Jay Grinney, President and ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31
... Management to discuss positive corporate developments and ... call, SANTA CLARA, Calif., Oct. 14 ... cardiac diagnostic and services company, today,announced that ... discuss,recent corporate developments and provide an update ...
... release date, NATICK, Mass., Oct. 14 ... the following comments reinforcing,the strength of its balance ... and the Company,s stock price,volatility have had no ... performance of the Company. Strong cash flow generation,during ...
... China, Oct. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) ... pharmaceutical, biotechnology and,medical device research and development ... United States, today announced preliminary selected,unaudited financial ... 30, 2008,and updated its guidance for the ...
Cached Biology Technology:NewCardio Management to Host Conference Call on October 21 2NewCardio Management to Host Conference Call on October 21 3Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet 2Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 2WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 4WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 5WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 6WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 7WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 8
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... New combinations of agents based on the oldest synthetic ... spread of malaria parasites and make a significant contribution ... "Roll Back Malaria Initiative." In a study on 160 ... medicine from the Heidelberg University Hospital have shown that ...
... Wash. -- Some researchers hope to turn plants into ... this, scientists have to learn how to convert plant ... cheaply and efficiently. In new research, chemists have successfully ... directly into the building block called HMF in one ...
... Individuals with heart disease are twice as likely to ... the medical community has largely been unable to explain. ... Hospital, in conjunction with The Montral Heart Institute, University ... genetic variations that contribute to depression in heart disease ...
Cached Biology News:Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2Genetic factors may predict depression in heart disease patients 2Genetic factors may predict depression in heart disease patients 3
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Mouse monoclonal [88B] to nicotinic Acetylcholine Receptor ( Abpromise for all tested applications)....
D4-GDI rabbit polyclonal antibody...
Biology Products: